ELEVAI Labs to Accelerate and Expand its Work With Stem Cell-Derived Exosomes After Securing New Research Partnership and Non-Repayable Grant

ELEVAI Secured its Non-Repayable Grant From the Mitacs Accelerate Grants Program (Mitacs) and Will Be Conducting its Research Partnership With Dr. Stanislav Sokolenko’s Lab at Dalhousie University

ELEVAI Labs, a medical aesthetic biotechnology company specializing in physician-dispensed skincare, reported today that it secured a stem cell exosome research partnership with Dr. Stanislav Sokolenko’s Lab at Dalhousie University and a non-repayable Grant from the Mitacs Accelerate Grants Program (Mitacs). Mitacs is an organization that funds projects intended to grow research and development initiatives between industry and institutions.

About Project ELV3000

ELV3000 is a two-year research collaboration between Dr. Sokolenko’s Lab and ELEVAI LABS. The primary aim of this research project is to establish novel techniques for characterizing the bioactive ’payload’ of ELEVAI LABS’ exosomes and provide ELEVAI with a greater understanding of how specific exosome contents may be attributable to positive skincare outcomes.

The secondary goal of the project is to further optimize the ELEVAI Exosome™ production process, which may improve product efficacy through the ability to exert greater control over exosome payloads. The ELEVAI E-Series™ is currently the first-to-market topical exosome product series intentionally developed to support skin before and after energy-based procedures to optimize aesthetic outcomes and elevate the patient experience. The resulting process improvements are expected to result in new and improved products designed to markedly improve the appearance of the skin, scalp, and hair.

WealthyVC.com Kicks Off Coverage of the Emerging and Recession Resilient Cosmeceuticals Industry

Commenting on today’s  announcement, ELEVAI Labs Founder Jordan R. Plews, Ph.D., stated:

“We are excited to be working with Dr. Sokolenko to further understand the protein dynamics of our stem cell exosomes. This partnership will continue to accelerate and expand ELEVAI’s innovation capabilities and, with the help of our other research partners, enable ELEVAI to continue to rapidly improve proprietary manufacturing processes and innovative products to better serve the medical aesthetics community and beyond.” 

Dr. Stanislav Sokolenko added:

“My team and I are very excited to work with ELEVAI. Exosome production is a rapidly growing field, and developing robust characterization strategies will be essential moving forward. My lab has first-hand experience in the development and characterization of new analytical methods/software that we are eager to apply as part of ELV3000. The underlying challenge in this type of work always remains the same: to separate signal from noise and generate conclusions that are both biologically and statistically sound.”

Dr. Stanislav Sokolenko earned his Ph.D. from the University of Waterloo in 2016, where he received the UW Outstanding Achievement Award for Ph.D. Research. After a brief postdoctoral at the University of Nantes, he joined the Department of Process Engineering and Applied Science at Dalhousie University in 2017.

View the original ELEVAI Labs press release here.

For more information, visit the ELEVAI Skincare website here.

Interested in buying ELEVAI Skincare products? Click here to find an authorized ELEVAI Skincare Professional.

Please consider Following Us on Social Media via the Wealthy VC social links below to stay up to date on Elevai Labs.

????Join the Discussion in the Wealthy VC Investor Group

????Have a Stock Tip or New  Story Suggestion? Email us at Invest@WealthyVC.com

Elevai Labs Inc. is a paid client of Wealthy VC.

Wealthy VC’s parent company has been compensated $13,500 per month for 12 months for investor relations, public relations, and market awareness services by Elevai Labs Inc.

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.

View Full Disclaimer Here